HomeWebinarsCustom LNP Formulation Development - The New Early Formulation Screening Service as a Key Partner for Success

Custom LNP Formulation Development - The New Early Formulation Screening Service as a Key Partner for Success


Nucleic acids are known to be fragile payloads. To enable their safe and efficient delivery into cells, the RNA payload needs to be “packed” into a delivery vehicle, the lipid nanoparticles (LNP). This webinar gives insight into our capabilities for customized LNP formulation development for novel therapeutic modalities. The manufacturing, optimization, analytical characterization, in vivo testing, and scale-up strategy for LNP will be discussed.

With our newly launched service, we aim at simplifying the road to market, by providing preclinical development service, delivering animal trial material (including for GLP tox studies) and supporting in-house transfer to clinical GMP manufacturing.

In this webinar, you will learn:

  • How to overcome obstacles in lipid nanoparticle formulation development
  • Key considerations for process and analytical development of lipid nanoparticles
  • About case studies highlighting customized lipid nanoparticle formulations that are ready to be transferred to clinical and commercial drug product development


Johanna Simon, Ph.D.

Johanna Simon, Ph.D.


Principial Scientist

Johanna Simon, Ph.D., is a principal scientist in the Early Formulation Screening Service in Life Science Services at MilliporeSigma. Her work focuses on the preclinical formulation development of custom lipid nanoparticles for nucleic acid modalities.

After receiving her Ph.D. in Chemistry, Johanna has continued her scientific career as a postdoctoral researcher with a focus on developing antibody-functionalized nanoparticles for targeted drug delivery in vivo. Johanna has authored 50+ peer-reviewed articles in leading journals in the field of drug delivery sciences.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?